How should I manage a patient with primary hyperaldosteronism (Conn syndrome) who presents with hypertension and acute pulmonary edema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Conn Syndrome with Hypertension and Pulmonary Edema

Immediately initiate aggressive diuresis with IV loop diuretics to treat the acute pulmonary edema, while simultaneously starting mineralocorticoid receptor antagonist therapy (spironolactone 25-50 mg daily initially) to address the underlying aldosterone excess driving the volume overload.

Acute Phase Management (Pulmonary Edema)

Your patient requires urgent treatment of the life-threatening pulmonary edema before addressing the underlying Conn syndrome definitively:

  • IV loop diuretics are first-line for acute decompensation. Higher doses are often needed in primary aldosteronism compared to essential hypertension 1
  • IV vasodilators may be added to rapidly reduce filling pressures and accelerate decongestion in hypertensive pulmonary edema 2
  • Correct hypokalemia aggressively before and during diuresis, as aldosterone excess causes significant potassium wasting
  • Monitor closely for volume status, electrolytes, and renal function

Critical caveat: Excessive decongestion can lead to low cardiac output and hypotension, particularly if there is concurrent valvular disease, so titrate carefully 2.

Concurrent PA-Specific Medical Therapy

While managing acute decompensation, immediately initiate mineralocorticoid receptor antagonist therapy rather than waiting for complete workup:

First-Line: Spironolactone

  • Start spironolactone 25-50 mg daily even during acute hospitalization 3, 4
  • Titrate up to 100-200 mg daily (maximum 400 mg) based on blood pressure and potassium response 1, 4
  • Monitor potassium and creatinine closely, especially when combined with ACE inhibitors or ARBs 4
  • Titrate dose to achieve renin normalization as a biomarker of adequate aldosterone blockade 3, 5

Alternative: Eplerenone

  • Use if spironolactone causes intolerable side effects (gynecomastia, erectile dysfunction, menstrual irregularities) 4, 6
  • Requires 2-3 times higher doses than spironolactone (typically 50-100 mg twice daily) 6
  • More expensive but fewer anti-androgenic effects 7

Second-Line: Amiloride

  • 10-20 mg daily for patients intolerant to all MRAs 1, 8
  • Less effective than MRAs but provides ENaC blockade

Additional Antihypertensives

  • Add thiazide diuretics, calcium channel blockers, or beta-blockers as needed for blood pressure control 1, 4
  • Avoid relying solely on ACE inhibitors or ARBs - they show only modest efficacy in PA 4

Subacute Management (Post-Stabilization)

Once the patient is stabilized from pulmonary edema:

Determine Lateralization (Unilateral vs Bilateral Disease)

This determines definitive treatment approach:

  1. CT or MRI imaging of adrenals to identify adenomas 4

    • However, imaging alone is insufficient - functional confirmation is required
  2. Adrenal venous sampling (AVS) is the gold standard for lateralization 4, 7

    • Perform at experienced centers (success rate ~95%) 7
    • Corrected aldosterone/cortisol ratio >4:1 indicates unilateral source 7
    • Essential before surgery - imaging alone would lead to inappropriate surgery in 25% of cases 7
  3. Consider genetic testing for glucocorticoid-remediable aldosteronism if:

    • Family history of PA or stroke <40 years
    • Hypertension onset ≤20 years 4

Definitive Treatment Based on Lateralization

Unilateral Disease (Aldosterone-Producing Adenoma):

  • Laparoscopic adrenalectomy is the treatment of choice 1, 4, 6, 9
  • Pretreat for 8-10 weeks with spironolactone to correct metabolic abnormalities and control blood pressure before surgery 1, 8
  • Expect 100% cure of hypokalemia, but only 30-60% complete cure of hypertension 7
  • Many patients remain hypertensive post-operatively and require continued antihypertensive therapy 1, 4

Bilateral Disease (Idiopathic Hyperplasia) or Non-Surgical Candidates:

  • Lifelong medical therapy with MRAs 4, 6, 9
  • Continue spironolactone as outlined above
  • Add conventional antihypertensives as needed for blood pressure control

Key Monitoring Parameters

  • Blood pressure targets: Normalize BP with fewest medications 5
  • Serum potassium: Normalize when hypokalemic 5
  • Renin levels: Titrate MRA dose to increase renin from baseline - this serves as a biomarker of adequate aldosterone blockade 3, 5
  • Renal function: Treatment may unmask underlying renal disease with creatinine increase and eGFR decrease 4
  • Sodium restriction: Strongly encourage dietary sodium restriction (<2g/day) as it reduces the substrate fueling PA pathophysiology and enhances MRA efficacy 5

Critical Clinical Pearls

Why this patient developed pulmonary edema: Aldosterone excess causes inappropriate sodium retention, volume expansion, and cardiovascular remodeling beyond what occurs in essential hypertension 6. This explains the acute decompensation and emphasizes why PA-specific therapy (not just generic antihypertensives) is essential.

Don't delay MRA therapy: The 2025 Endocrine Society guidelines 3 and 2024 ESC guidelines 9 support early initiation of PA-specific therapy, even during acute hospitalization. Aldosterone excess itself causes myocardial fibrosis, left ventricular hypertrophy, and increased cardiovascular mortality independent of blood pressure control 7.

Post-treatment surveillance: Even after successful adrenalectomy, patients require lifelong follow-up as many remain hypertensive and need continued treatment per standard hypertension guidelines 1, 4.

References

Guideline

primary aldosteronism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2025

Research

Treatment of Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979), 2026

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.